{
  "abstract": "Objective: To investigate the association between rivaroxaban combined with clopidogrel therapy and thrombotic risk, platelet activation, myocardial injury biomarkers, and clinical outcomes in patients with coronary artery ectasia (CAE).\n\nMethods: This single-center retrospective cohort study included 158 consecutive patients with CAE diagnosed by coronary angiography between June 2023 and June 2025. Patients receiving clopidogrel alone or rivaroxaban plus clopidogrel were compared. A 1:1 nearest-neighbor propensity score matching method was applied, generating 70 matched pairs. Thrombotic risk markers, including D-dimer (D-D), thrombin-antithrombin complex (TAT), and von Willebrand factor (vWF), platelet activation parameters [ADP-induced platelet aggregation rate (ADP-PAg) and CD62P], thromboelastography parameters [maximum amplitude (MA) and reaction time (R)], and myocardial injury-related biomarkers [high-sensitivity cardiac troponin T (hs-cTnT), creatine kinase-MB (CK-MB), heart-type fatty acid-binding protein (H-FABP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP)] were evaluated at baseline and 6 months. Clinical outcomes, including thrombotic-related adverse cardiovascular events and bleeding events, were recorded during 12 months of follow-up.\n\nResults: After propensity score matching, baseline characteristics were well balanced between groups. At 6 months, patients receiving rivaroxaban plus clopidogrel showed lower levels of D-D, TAT, vWF, ADP-PAg, CD62P, MA, hs-cTnT, CK-MB, H-FABP, and NT-proBNP, as well as prolonged R values, compared with those receiving clopidogrel alone (all P < 0.05). During follow-up, thrombotic-related adverse cardiovascular events occurred less frequently in the combination therapy group than in the clopidogrel group (7.14% vs. 20.00%, P = 0.027). Minor bleeding events were numerically higher in the combination therapy group (17.14% vs. 10.00%, P = 0.218), while no intracranial or fatal bleeding events occurred.\n\nConclusion: Among patients with CAE, rivaroxaban combined with clopidogrel was associated with more favorable changes in coagulation activation, platelet activity, myocardial injury biomarkers, and thrombotic-related clinical outcomes compared with clopidogrel alone. These findings suggest that combined anticoagulant and antiplatelet therapy may represent a potential strategy for selected high-risk patients with CAE. Further multicenter prospective studies are required to confirm these observations.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cardiology, Cangzhou Central Hospital of Hebei Medical University , , ,",
    "Department of Cardiology, The Second Hospital of Tianjin Medical University , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tao Geng"
    },
    {
      "affs": [
        0
      ],
      "name": "Mengwei Feng"
    },
    {
      "affs": [
        0
      ],
      "name": "Yunjie Wu"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhaoqing Xie"
    },
    {
      "affs": [
        0
      ],
      "name": "Jingxian Xing"
    },
    {
      "affs": [
        0
      ],
      "name": "Deguang Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Xue Liang"
    },
    {
      "affs": [
        0
      ],
      "name": "Juan Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Hui Gao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0bxzdv95nyx4g.bib",
  "cited_by": 0,
  "doi": "10.3389/fcvm.2026.1912975",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690761/?tool=EBI",
  "id": "0bxzdv95nyx4g",
  "issns": [
    "2297-055X"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13690761",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2705|Antiplatelet Therapy and Cardiovascular Diseases"
    ]
  ],
  "openalex": "W7221169989",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690761/pdf/?tool=EBI",
  "pmcid": "PMC13690761",
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/0bxzdv95nyx4g.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:59Z",
      "native_id": "PMC:PMC13690761",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13690761"
    },
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "10.3389/fcvm.2026.1912975",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fcvm.2026.1912975/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2705|Antiplatelet Therapy and Cardiovascular Diseases",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Effects of rivaroxaban combined with clopidogrel on thrombotic risk and myocardial injury indicators in patients with coronary artery ectasia",
  "title_text": "Effects of rivaroxaban combined with clopidogrel on thrombotic risk and myocardial injury indicators in patients with coronary artery ectasia",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/0bxzdv95nyx4g",
  "venue": "Frontiers in cardiovascular medicine",
  "versions": []
}